Ask AI
BTK Therapies in RR CLL

CME

From ASH 2025 to the Clinic: Global Perspectives on Evolving BTK Therapies in Relapsed/Refractory CLL

Physicians: Maximum of 0.50 AMA PRA Category 1 Credit

Released: March 12, 2026

Expiration: September 11, 2026

Pretest

Progress
1 2 3
Course Completed
Please answer the questions below.
1.

In my current practice, I am confident in my ability to apply recently presented clinical trial data to inform treatment selection and sequencing for patients with relapsed/refractory CLL.